Medical Microinstruments raised $125 million in a series D after installing about 50 Symani microsurgery robots worldwide and supporting 3,500 complex procedures, as it pushes the FDA-cleared platform into broader commercial markets. For clinicians, the signal is that robotic microsurgery is gaining enough traction in breast reconstruction, lymphatic repair and other precision procedures to attract late-stage growth funds.

Why It Matters To Oncology

• Symani is already being used in open microsurgical procedures relevant to cancer care, including post-mastectomy breast cancer reconstruction and lymphatic system repair.

• The platform’s NanoWrist instruments offer seven degrees of freedom, tremor filtration and motion scaling, features aimed at improving precision in delicate tissue transfer and anastomosis.

• That matters for oncology centers looking to expand reconstructive and lymphedema-related capabilities tied to survivorship care.

The Financials

• The $125 million series D came less than a month after MMI secured €17 million ($19.1 million) in additional funding.

• BioStar Capital led the round, with S3 Ventures and Angelini Ventures joining as new investors.

• The raise builds on the $110 million MMI brought in during its series C two years ago.

What They're Saying

• CEO Mark Toland said the roughly 50 installed systems and 3,500 procedures show “there is demand for robotic microsurgery at leading institutions around the world.”

• He added the new capital will help MMI “accelerate adoption and continue advancing the platform through innovation in areas like energy instruments and digital surgery capabilities.”

What's Next

• MMI plans to use the funds to broaden Symani’s commercial footprint and support additional clinical trials.

• That includes the REMIND study, which is evaluating the safety and feasibility of using Symani to re-establish lymphatic drainage pathways in the deep cervical lymph nodes of patients with Alzheimer’s disease and confirmed lymphatic abnormalities.

• For oncology watchers, the nearer-term focus is whether MMI can translate installed-base growth into wider adoption across reconstructive, lymphatic and nerve-related microsurgery workflows.